41 results
8-K
EX-99.1
UNCY
Unicycive Therapeutics Inc
13 May 24
Unicycive Announces First Quarter 2024 Financial Results and Provides Business Update
4:28pm
Ltd.
Research and development (R&D) Expenses: R&D expenses were $6.8 million for the three months ended March 31, 2024, compared to $3.0 million … for the three months ended March 31, 2023. The increase in research and development expenses was primarily due to one time costs related to the OLC
8-K
EX-99.1
44sm1eeebd6h6y9
14 Nov 23
Unicycive Announces Third Quarter 2023 Financial Results and Provides Business Update
4:42pm
8-K
EX-99.1
j7tb u90a9pbhhcrr9
6 Sep 23
Unicycive Therapeutics Strengthens Board of Directors with Appointment of Sara Kenkare-Mitra, PhD
9:16am
8-K
4os4l542 p68d6qsoz
6 Sep 23
Unicycive Therapeutics Strengthens Board of Directors with Appointment of Sara Kenkare-Mitra, PhD
9:16am
8-K
EX-99.1
x7lcy yun
14 Aug 23
Unicycive Announces Second Quarter 2023 Financial Results and Provides Business Update
9:19pm
8-K
EX-99.1
h9tkzjyngts2i6hei
16 May 23
Unicycive Announces First Quarter 2023 Financial Results and Provides Business Update
10:30am
8-K
EX-99.1
19jd0bqa
31 Mar 23
Unicycive Announces Full Year 2022 Financial Results and Provides Business Update
7:47am
8-K
EX-99.1
9q21nqpw
14 Nov 22
Unicycive Announces Third Quarter Financial Results and Provides Business Update
9:49am
S-3
pwimh53gqvsvys1miv
15 Aug 22
Shelf registration
6:20pm
8-K
EX-99.1
67kpv16yjqu 2teh
15 Aug 22
Unicycive Announces Second Quarter Financial Results and Provides Business Update
6:18pm